Launch Lab Partners Logo
Contact

Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia

DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first MHRA approved treatment in the UK to slow the progression of myopia in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D.

This approval comes after authorization by the European Commission and the initial launch in Germany earlier this year. Sydnexis’ low-dose atropine eye drop SYD-101 is licensed to Santen in Europe, the Middle East, and Africa, which Santen commercializes under the brand name Ryjunea®. Santen is a global pharmaceutical company with over 135 years of experience dedicated to advancing eye health and improving lives through better vision.

“We are thrilled that the MHRA has granted approval of Ryjunea® to Santen, marking another important milestone in bringing this innovative therapy to even more patients in need,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “Backed by the global STAR study, this announcement underscores the potential of an approved low-dose atropine solution to address a significant unmet medical need for children with progressive myopia worldwide.”

About Sydnexis, Inc.

Sydnexis, Inc. is a biopharmaceutical company dedicated to advancing care for pediatric progressive myopia. The company’s lead compound, SYD-101, is currently approved in the European Union, where it is licensed to Santen S.A. and marketed as Ryjunea®. Sydnexis is supported by leading life-science investors, including Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. For more information on Sydnexis, please visit www.sydnexis.com.

Contacts

For media inquiries, please contact:

FTI Consulting
Robert Stanislaro or Helen O’Gorman
sydnexis@fticonsulting.com

Social Media

Linkedin-in

Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia

Co-Founder & Co-CEO, Marketing & Brand Experience

Jenna is passionate about advancing patient access to advanced healthcare innovations and leveraging her significant experience in marketing and brand development in service of that passion. With over 15 years of medical device marketing experience in ophthalmology and bariatrics, she specializes in global commercialization, product launches, clinical trial patient recruitment, branding, messaging, internet marketing strategies, and developing comprehensive marketing assets to support growth initiatives.

Prior to co-founding LaunchLab Partners, Jenna led Global Marketing for AcuFocus, a privately held medical device company based in Southern California. At AcuFocus she spearheaded the company’s global marketing strategy and led execution of the company’s brand and market development initiatives, launching first-of-their-kind products.

Jenna holds a B.A. in Marketing from San Diego State University and a certificate in Advanced Digital Marketing Growth strategies from the Wharton School of the University of Pennsylvania. She also serves as a digital ambassador for the Ophthalmic World Leaders (OWL) and is a member of Women in Ophthalmology.

A self-identified Peloton enthusiast (#BeKindGoFarr), Jenna is committed to action, growth, community, and achievement.

Back to Team